Answers are grounded in this paper and cite their sources.
Randomized trial investigates cyclosporine A's protective effects against rhabdomyolysis caused by wasp venom, suggesting new treatment options.
OBJECTIVE: Wasp venom-induced rhabdomyolysis (RM) is a life-threatening syndrome characterized by skeletal muscle damage and systemic complications. The core mechanism is closely associated with mitochondrial-mediated energy metabolism disturbances. This study aims to investigate the role of the mitochondrial-mediated Cyclophilin D (CypD)-mitochondrial permeability transition pore (mPTP) pathway in wasp venom-induced RM and the protective mechanism of cyclosporine A (CsA). METHODS: Rats were randomly assigned to five groups according to a random number table: control group, normal saline (NS) group, CsA monotherapy group, venom control group (V) group, and V + CsA intervention group. RESULTS: Compared to the control group, the V group exhibited significantly elevated serum levels of CK, AST, ALT, and Cr (P < 0.01). Additionally, levels of pro-inflammatory cytokines (IL-2, IFN-γ, TGF-β) were notably increased (P < 0.01). Histological examinations of skeletal muscle tissue revealed significant myofiber disruption, myocyte lysis and necrosis, mitochondrial structural damage, and signs of apoptosis. Furthermore, the total protein expressions of cytochrome c (CytC), caspase-3 (Caspase-3), and CypD were all significantly upregulated (P < 0.01). Treatment with CsA significantly ameliorated these injuries. CONCLUSION: This study successfully established a rat model of wasp venom-induced rhabdomyolysis. The abnormal opening of the CypD-mediated mPTP is one of the potential mechanisms underlying wasp venom-induced RM. CsA mitigates RM by inhibiting the CypD-mPTP pathway, providing a new therapeutic target for muscle injury induced by wasp venom.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: